- Corporate Officers - T
- Thomas Frank E
Insider Trading History of Thomas Frank E
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Thomas Frank E since 2007.
This trader's CIK number is 1242616.
At the time of last reporting, Thomas Frank E was the Director of Larimar Therapeutics, Inc.. (stock ticker symbol LRMR).
Also see all insider trading activities at Larimar Therapeutics, Inc..
Note that in the past
THOMAS FRANK E also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Critical Therapeutics Inc (CRTX) by Thomas Frank E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2007 | CRTX | 5,000 | $10,500 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Orchard Therapeutics Plc (ORTX) by Thomas Frank E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | ORTX | 0 | $0 | 0 | $0 | 40,000 | $18,360 |
| 2022 | ORTX | 10,000 | $7,470 | 0 | $0 | 0 | $0 |
| 2021 | ORTX | 0 | $0 | 0 | $0 | 10,000 | $24,400 |
| 2020 | ORTX | 0 | $0 | 0 | $0 | 10,000 | $24,400 |
Yearly summary of insider trading at Larimar Therapeutics, Inc. (LRMR) by Thomas Frank E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | LRMR | 2,000 | $22,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Amag Pharmaceuticals, Inc. (AMAG) by Thomas Frank E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2015 | AMAG | 0 | $0 | 35,000 | $2,393,049 | 15,000 | $223,650 |
| 2013 | AMAG | 0 | $0 | 10,000 | $155,970 | 20,000 | $0 |
| 2012 | AMAG | 2,000 | $33,665 | 5,000 | $75,400 | 10,000 | $0 |
Insider trading activities at 4 companies by Thomas Frank E:
1. Critical Therapeutics Inc (CRTX)
2. Orchard Therapeutics Plc (ORTX)
3. Larimar Therapeutics, Inc. (LRMR)
4. Amag Pharmaceuticals, Inc. (AMAG)
Table 1. Insider trading of Critical Therapeutics Inc (CRTX) by Thomas Frank E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2007-08-22 | CRTX | Buy | 5,000 | 2.10 | 10,500 |
Table 2. Insider trading of Orchard Therapeutics Plc (ORTX) by Thomas Frank E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-03-10 | ORTX | Option Ex | 20,000 | .46 | 9,180 |
| 2023-02-09 | ORTX | Option Ex | 20,000 | .46 | 9,180 |
| 2022-04-01 | ORTX | Buy | 10,000 | .75 | 7,470 |
| 2021-01-29 | ORTX | Option Ex | 10,000 | 2.44 | 24,400 |
| 2020-06-11 | ORTX | Option Ex | 10,000 | 2.44 | 24,400 |
Table 3. Insider trading of Larimar Therapeutics, Inc. (LRMR) by Thomas Frank E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-02-14 | LRMR | Buy | 2,000 | 11.00 | 22,000 |
Table 4. Insider trading of Amag Pharmaceuticals, Inc. (AMAG) by Thomas Frank E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2015-08-05 | AMAG | Option Ex | 15,000 | 14.91 | 223,650 |
| 2015-08-05 | AMAG | Sale | 15,000 | 66.85 | 1,002,749 |
| 2015-06-04 | AMAG | Sale | 20,000 | 69.52 | 1,390,300 |
| 2013-01-03 | AMAG | Option Ex | 20,000 | .00 | 0 |
| 2013-01-03 | AMAG | Sale | 10,000 | 15.60 | 155,970 |
| 2012-11-30 | AMAG | Option Ex | 10,000 | .00 | 0 |
| 2012-11-30 | AMAG | Sale | 5,000 | 15.08 | 75,400 |
| 2012-04-02 | AMAG | Buy | 500 | 15.86 | 7,930 |
| 2012-03-01 | AMAG | Buy | 500 | 15.81 | 7,905 |
| 2012-02-01 | AMAG | Buy | 500 | 16.56 | 8,280 |
| 2012-01-03 | AMAG | Buy | 500 | 19.10 | 9,550 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Thomas Frank E
(Director of Larimar Therapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.